Characterization and implications of host‐cell protein aggregates in biopharmaceutical processing
Biotechnology and Bioengineering · 2023
DOI: 10.1002/bit.28325 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology and Bioengineering, 2023. Verfasst von Young Hoon Oh und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware, USA. Hauptthemen laut MEDLINE: Protein Aggregates, Biological Products. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Institute for Innovation in Manufacturing Biopharmaceuticals.
Abstract (Originalsprache)
In the production of biopharmaceuticals such as monoclonal antibodies (mAbs) and vaccines, the residual amounts of host‐cell proteins (HCPs) are among the critical quality attributes. In addition to overall HCP levels, individual HCPs may elude purification, potentially causing issues in product stability or patient safety. Such HCP persistence has been attributed mainly to biophysical interactions between individual HCPs and the product, resin media, or residual chromatin particles. Based on measurements on process streams from seven mAb processes, we have found that HCPs in aggregates, not necessarily chromatin‐derived, may play a significant role in the persistence of many HCPs. Such aggregates may also hinder accurate detection of HCPs using existing proteomics methods. The findings also highlight that certain HCPs may be difficult to remove because of their functional complementarity to the product; specifically, chaperones and other proteins involved in the unfolded protein response (UPR) are disproportionately present in the aggregates. The methods and findings described here expand our understanding of the origins and potential behavior of HCPs in cell‐based biopharmaceutical processes and may be instrumental in improving existing techniques for HCP detection and clearance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware, USA.
- Purification Process Development, Genentech, Inc., South San Francisco, California, USA.
- Analytical Research and Development, Merck & Co., Inc., Kenilworth, New Jersey, USA.
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey, USA.
- Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York, USA.
- Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, North Carolina, USA.
ORCID-Profile: Kelvin H Lee, Steven M Cramer, Abraham M Lenhoff
Förderung
- National Institute for Innovation in Manufacturing Biopharmaceuticals
Zitieren
APA
Oh, Y. H., Becker, M. L., Mendola, K. M., Choe, L. H., Min, L., Lee, K. H., Yigzaw, Y., Seay, A., Bill, J., Li, X., Roush, D. J., Cramer, S. M., Menegatti, S., & Lenhoff, A. M. (2023). Characterization and implications of host‐cell protein aggregates in biopharmaceutical processing. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28325
Vancouver
Oh YH, Becker ML, Mendola KM, Choe LH, Min L, Lee KH, et al. Characterization and implications of host‐cell protein aggregates in biopharmaceutical processing. Biotechnology and Bioengineering. 2023. doi:10.1002/bit.28325
BibTeX
@article{Oh2023,
author = {Oh, Young Hoon and Becker, Matthew L and Mendola, Kerri M and Choe, Leila H and Min, Lie and Lee, Kelvin H and Yigzaw, Yinges and Seay, Alexander and Bill, Jerome and Li, Xuanwen and Roush, David J and Cramer, Steven M and Menegatti, Stefano and Lenhoff, Abraham M},
title = {Characterization and implications of host‐cell protein aggregates in biopharmaceutical processing},
journal = {Biotechnology and Bioengineering},
year = {2023},
doi = {10.1002/bit.28325}
}
EUVIMED